Adaptimmune Therapeutics plc
https://www.adaptimmune.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Adaptimmune Therapeutics plc
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Keeping Track: Iovance’s Amtagvi Approval Brings T Cell Therapy To Solid Tumors
Melanoma treatment Amtagvi is US FDA’s biologics center’s first novel approval of 2024.
As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Targeting Solid Cancers With CAR-T: Japan’s Noile-Immune Looks To Partner Platform
Setting a strategic focus on solid cancers with its enhanced PRIME CAR-T technology, Koji Tamada, CEO of Noile-Immune, shared the Japanese bioventure's collaboration strategies and views on the next generation of cell therapies.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Adaptimmune LLC
- Adaptimmune Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice